Hypera（HYPE3）株式概要
Hypera S.A.はブラジルで製薬会社として営業している。 詳細
HYPE3 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hypera S.A. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | R$22.67 |
| 52週高値 | R$28.87 |
| 52週安値 | R$20.66 |
| ベータ | 0 |
| 1ヶ月の変化 | -3.49% |
| 3ヶ月変化 | -4.87% |
| 1年変化 | -6.32% |
| 3年間の変化 | -43.87% |
| 5年間の変化 | -37.05% |
| IPOからの変化 | 171.50% |
最新ニュース
分析記事 • May 07
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...
ナラティブの更新 • Feb 05
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).Recent updates
分析記事 • May 07
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...ナラティブの更新 • Feb 05
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).ナラティブの更新 • Jan 20
HYPE3: Slight Index Exit And Firm P/E Outlook Will Support Upside
Analysts have nudged their price target for Hypera slightly lower to reflect small adjustments in fair value, discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a modest trim of about R$0.15 per share. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how some index and benchmark aware investors treat the stock (Key Developments).ナラティブの更新 • Jan 05
HYPE3: Future P/E Multiple Expansion Will Support Further Upside Potential
Analysts have slightly increased their price target on Hypera to reflect updated fair value estimates and adjustments to revenue growth, profit margin expectations, and future P/E assumptions. What's in the News Hypera S.A. is scheduled to hold a board meeting on Dec 11, 2025, which may address governance, capital allocation, or operational planning (company event filing).分析記事 • Dec 28
Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブの更新 • Dec 15
HYPE3: Future P E Expansion Will Support Further Upside Potential
Analysts have slightly raised their price target on Hypera to $30.24 from $30.14, citing modestly stronger revenue growth expectations that more than offset a small downward revision in projected profit margins and a higher implied future P/E multiple. Valuation Changes Fair Value Estimate has risen slightly from R$30.14 to R$30.24 per share, reflecting a modestly higher intrinsic valuation.分析記事 • Dec 01
What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E
When close to half the companies in Brazil have price-to-earnings ratios (or "P/E's") below 9x, you may consider Hypera...ナラティブの更新 • Dec 01
HYPE3: Future P/E Expansion Signals Continued Upside Potential
Analysts have increased their price target for Hypera from $29.59 to $30.14, citing revised estimates that reflect a slightly higher discount rate as well as updated projections for revenue growth and profit margin. Valuation Changes Fair Value: Increased slightly from R$29.59 to R$30.14 per share.分析記事 • Nov 05
Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think
Hypera S.A.'s ( BVMF:HYPE3 ) stock showed strength, with investors undeterred by its weak earnings report. We think...分析記事 • Sep 05
Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Aug 10
Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next
It's been a sad week for Hypera S.A. ( BVMF:HYPE3 ), who've watched their investment drop 10% to R$23.19 in the week...分析記事 • Jun 15
The Price Is Right For Hypera S.A. (BVMF:HYPE3)
With a price-to-earnings (or "P/E") ratio of 21.7x Hypera S.A. ( BVMF:HYPE3 ) may be sending very bearish signals at...分析記事 • Apr 23
Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Mar 27
Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture
Hypera S.A.'s ( BVMF:HYPE3 ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
新しいナラティブ • Mar 23
Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations
Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements.分析記事 • Feb 24
Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E
With a median price-to-earnings (or "P/E") ratio of close to 8x in Brazil, you could be forgiven for feeling...分析記事 • Nov 21
More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%
To the annoyance of some shareholders, Hypera S.A. ( BVMF:HYPE3 ) shares are down a considerable 27% in the last month...分析記事 • Nov 14
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Oct 03
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
There wouldn't be many who think Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10x is worth a...分析記事 • Jul 13
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 20
Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10.9x right now seems...分析記事 • Mar 16
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Hypera S.A. ( BVMF:HYPE3 ) had a good week, as its shares rose 3.3% to close at R$34.10 following the...分析記事 • Feb 21
Is Hypera (BVMF:HYPE3) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jan 09
Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Dec 22
Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 12.7x right now seems...分析記事 • Nov 02
Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Aug 27
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Jul 21
Is Hypera (BVMF:HYPE3) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Apr 15
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Feb 19
With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Jan 03
We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Oct 11
Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Jul 31
Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Hypera S.A. ( BVMF:HYPE3 ) shareholders, because the company has just released its latest...分析記事 • Jul 19
Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 28
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Apr 14
Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Mar 25
I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...分析記事 • Mar 04
Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 13x might make it look like a sell right now...株主還元
| HYPE3 | BR Pharmaceuticals | BR 市場 | |
|---|---|---|---|
| 7D | -3.0% | -0.2% | -0.7% |
| 1Y | -6.3% | 20.5% | 15.0% |
業界別リターン: HYPE3過去 1 年間で20.5 % の収益を上げたBR Pharmaceuticals業界を下回りました。
リターン対市場: HYPE3は、過去 1 年間で15 % のリターンを上げたBR市場を下回りました。
価格変動
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 8.4% |
| 10% least volatile stocks in BR Market | 1.9% |
安定した株価: HYPE3 、 BR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: HYPE3の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1999 | 10,564 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A.はブラジルで製薬会社として営業している。Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR、Flow、Garasone、Halobex、Lipanon、Luna、moon、Lydian、macrodantin、MaxSulid、Milgamma、Mioflex - A、Nesina、Novotram、Oximax、Peridal、Peridal Suspension、PredSim、Pressaliv、Quadriderm、Rizi、Rizi M、Softalm、Tacroz、Tinodin、Umma、velunidブランド。また、マンテコープ・スキンケアのブランドで日焼け止めと保湿スキンケア製品を、同様のブランドでドラージナ、ドロピーD、エクイリブリス、バランス、フラボニド、ヒスタミン、ネオフレッシュ、ネオレフリン、ネオキミカ・ビタミン、ネオソラム、トルシラックスを提供している；市販薬ではApracur、Benegrip、Buscopan、Coristina D Pro、Engov、Epocler、Estomazil、Neosaldinaの各ブランドと、Neo Químicaブランドの類似薬およびジェネリック医薬品がある。さらに、Tamarine、Biotônico Fontoura、Zero-Calブランドの栄養・ビタミンサプリメント製品、Hydroxyzine、Sodium Diclofenac、Dipyron、Ibuprofen、Losartan Potassium、Mal Dexchlorpheniramine、Naproxene、Paracetamol、Simethicon、Loratadine、Omeprazole、Tadalaphyl、Desogestrelブランドのジェネリック医薬品も提供している。同社は以前はHypermarcas S.A.として知られていたが、2018年2月にHypera S.A.に社名を変更した。Hypera S.A.は1999年に設立され、ブラジルのサンパウロに本社を置いている。
Hypera S.A. 基礎のまとめ
| HYPE3 基礎統計学 | |
|---|---|
| 時価総額 | R$15.95b |
| 収益（TTM） | R$1.20b |
| 売上高(TTM) | R$7.70b |
13.3x
PER（株価収益率2.1x
P/SレシオHYPE3 は割高か？
公正価値と評価分析を参照収益と収入
| HYPE3 損益計算書（TTM） | |
|---|---|
| 収益 | R$7.70b |
| 売上原価 | R$3.15b |
| 売上総利益 | R$4.55b |
| その他の費用 | R$3.35b |
| 収益 | R$1.20b |
直近の収益報告
Dec 31, 2025
次回決算日
Aug 06, 2026
| 一株当たり利益（EPS） | 1.70 |
| グロス・マージン | 59.04% |
| 純利益率 | 15.53% |
| 有利子負債／自己資本比率 | 74.6% |
HYPE3 の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
5.2%
現在の配当利回り62%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 07:16 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Hypera S.A. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22
| アナリスト | 機関 |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |